LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and ...
Zacks Investment Research on MSN
Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings
Eli Lilly and Company LLY will report its third-quarter 2025 earnings on Oct. 30, before market open. The Zacks Consensus ...
Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound. Q3 2025 EPS increased by $5.14 to $6.21 on a reported ...
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...
Zacks Investment Research on MSN
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
Eli Lilly and Company’s LLY stock has risen 9.5% in a month, mainly due to the recent recovery in the pharma sector. The drug and biotech sector has recovered in the past month, with large drugmakers ...
The company's multibillion-dollar investments in manufacturing in the U.S. are likely to be warmly welcomed by the Trump administration. Eli Lilly's management has already committed to taking action ...
Drug giant Eli Lilly is launching an AI-powered drug discovery platform. While it won't generate any revenue, this initiative could pay off in the long run. Still, there are plenty of other reasons to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback